Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-23-201707
Filing Date
2023-08-02
Accepted
2023-08-02 16:06:39
Documents
94
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q d524993d10q.htm   iXBRL 10-Q 2855881
2 EX-10.1 d524993dex101.htm EX-10.1 493030
3 EX-31.1 d524993dex311.htm EX-31.1 10849
4 EX-31.2 d524993dex312.htm EX-31.2 10834
5 EX-32 d524993dex32.htm EX-32 4333
  Complete submission text file 0001193125-23-201707.txt   14175179

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA teva-20230630.xsd EX-101.SCH 90769
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE teva-20230630_cal.xml EX-101.CAL 47177
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE teva-20230630_def.xml EX-101.DEF 571023
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20230630_lab.xml EX-101.LAB 600761
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20230630_pre.xml EX-101.PRE 603945
88 EXTRACTED XBRL INSTANCE DOCUMENT d524993d10q_htm.xml XML 3119067
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16174 | Film No.: 231135535
SIC: 2834 Pharmaceutical Preparations